Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — FBI Reveals That CBD Users Are Disqualified from Working at Agency

Last week, the FBI stated that the recent use of cannabis and components such as CBD automatically disqualified individuals from working at the agency. In a response to a question raised on Twitter, FBI Denver explained that while the use of CBD and cannabis was legal at the state level, their use was a disqualifier for  contractors and employees looking to work with the agency.

The handle went on to explain that individuals needed to wait at least a year from when they last used the substances before they applied to the federal agency. This is despite the fact that under the 2018 farm bill, hemp and derivatives such as CBD are federally legal.

In 2020, a separate field office stated that the agency’s employment policies for CBD were under review. Despite this, the FBI is yet to issue any new guidance that addresses CBD, which is widely available in many commercial markets across America.

A year later, the agency loosened its marijuana employment policy, making it so that individuals need only wait a year instead of three years before applying for a job at the agency. This new guidance was revised to omit a policy that restricted an individual’s eligibility based on the number of times they had consumed marijuana.

The earlier version stipulated that the use of cannabis or any of its forms, whether natural or synthetic, in any location regardless of its legality, more than 24 times after an individual had turned 18 disqualified them from employment at the agency.

While FBI candidates aren’t forbidden from using synthetic marijuana drugs approved by the FDA, the agency stresses that candidates can’t present prescriptions or medical cannabis cards as mitigating factors for cannabis or marijuana use.

Federal agencies have taken different approaches to marijuana employment policies as the legalization movement spreads across states in the country. For instance, the biggest union in the country, which represents federal employees, recently adopted an initiative supporting the legalization of marijuana. The union also called for the  end to policies that penalized federal workers who used marijuana responsibly after working hours in states where it was legal to be done away with.

Additionally, the Environment Protection Agency has highlighted that the use of marijuana by their workers is still prohibited. Its workers are also not allowed to directly invest in the marijuana industry.

In addition to this, the U.S. Forest Service recently posted a notice warning employees about the risks of consuming CBD products that were federally unregulated, noting that they were prohibited from using marijuana.

It is these contradictions between federal and state cannabis laws that create a complex environment for entities such as Advanced Container Technologies Inc. (OTC: ACTX) to operate and thrive.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Two Marijuana Policy Reform Bills Sent to California Governor’s Desk

California has been a pioneer in America’s cannabis industry. Among the first states to legalize recreational cannabis, California now generates billions of dollars in marijuana sales and is home to one of the largest cannabis industries in the world. As the end of the legislative season approaches, a slew of cannabis legislations have passed through the legislature.

Lawmakers have managed to pass several major cannabis bills, including ones that would enable interstate commerce, make the sealing of marijuana convictions more streamlined, and provide protections for insurance companies that serve the cannabis industry past; these bills are headed to Governor Gavin Newsom’s desk. There are still several other cannabis bills that haven’t made it that far, such as a bill that would provide job protections for people who consume cannabis on personal time and one that would bar local governments from prohibiting medical marijuana deliveries.

Two major cannabis bills that reached Newsom’s desk are SB 1326, introduced by Senator Anna Callabero, and AB 1706, introduced by Assemblymember Mia Bonta. If it is signed into law, SB 1326 would set up a framework for interstate cannabis commerce, allowing for trade between California’s cannabis industry and markets in other legal states. According to the bill, interstate marijuana commerce will be reliant on an official assurance that the trade does not put the state at risk of federal retaliation.

Coincidentally, New Jersey Senate president introduced legislation that would facilitate interstate cannabis commerce under similar conditions the same week that SB 1326 went through the Assembly Appropriations Committee. SB 1326 then advanced through the full chamber before the Senate approved it via a 298 to 9 vote.

AB 1706 is meant to bolster state law-mandated cannabis justice provisions by streamlining the record sealing process for prior cannabis convictions. The legislation would require courts to process cannabis conviction record sealing and other kinds of relief for eligible people with cannabis convictions within a set timeframe. More specifically, AB 1706 will give courts until March 1, 2023, to seal records for qualifying cannabis cases that had not been challenged by July 1, 2020.

After Senate amendments that changed record sealing reporting requirements from monthly to quarterly, AB 1706 advanced past the full chamber and then headed to the assembly where it was unanimously approved. Another bill — AB 2568 — was introduced by Assembly member Ken Cooley and would provide legal protections for companies that provide insurance-related services to businesses in the cannabis industry. All three bills, alongside bill AB 1954, which would protect patients who use medical cannabis, now await the governor’s signature.

Once these bills are signed into law and become operational, the regulatory environment in which companies such as Prime Harvest Inc. interact will be tad bit friendlier to the industry.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — How Marijuana Retailers Can Minimize Budtender Turnover

The American cannabis industry has been one of the most prolific job creators in recent times, creating hundreds of thousands of new jobs and generating billions of dollars in sales revenue. Of the entire class of cannabis employees, budtenders are probably the most recognized among cannabis users. This position interacts with customers the most, answering questions about different marijuana strains, medical applications and optimum methods of consumption.

However, the retail cannabis space is currently plagued by a high turnover of budtenders, an issue that could severely affect the industry in the long term. As the front face of cannabis retail stores, budtenders are usually the first point of contact between the customer and the business. To ensure that these individuals convey accurate and up-to-date information to customers, brands and cultivators invest significant amounts of money and time into training and educating budtenders about the products they offer.

The problem is that many budtenders leave soon after receiving this training, costing the companies that initially hired them cash as well as depriving them of much-needed expertise. The president of a California-based cannabis cultivator called Ember Valley says marijuana operators often spend time and resources building relationships with budtenders and similar employees who are on the front lines with the customer, only for them to leave.

A recent report from analytics firm Headset revealed that 55% of budtenders in the United States and Canada who had worked at a retail cannabis establishment in the past year had left “by the end of that time period.” Greenleaf Business Solutions president Mar Rodriguez posits that players in the cannabis sector have to legitimize the employee experience if they wish to retain budtenders.

Thanks to federal prohibition, the state-legal cannabis industry cannot access traditional banking services. This means that many employees in the sector are paid in cash, and many cannabis employers still don’t offer 401(k) plans or online pay stubs. Companies that offer these benefits in the cannabis space are few, Rodriguez says, and accessing these types of financial and banking services tends to be more costly for cannabis businesses compared to other industries.

On average, he estimates, cannabis businesses spend an extra $60,000 annually on payroll and employee services. For companies that simply can’t afford to offer these services, retaining employees can be a challenge. FutureSense CEO Jim Finkelstein believes that good leadership also plays a role in retaining employees, stating that the number-one reason people leave their jobs is because of poor leadership or not being provided enough tools to advance their skill sets.

Finkelstein says that even though companies can plan for high employee turnover by implementing a business strategy called “come, contribute, leave,” this strategy will hurt them in the long term, resulting in increased hiring costs and depriving companies of much-needed labor as well as raking up training costs. He pointed out strategies such as profit sharing and legitimizing employee experience that have been successful at retaining employees.

Since each cannabis company is unique in its internal dynamics, players such as Cannabis Strategic Ventures Inc. (OTC: NUGS) are likely to have their own mechanisms of attracting and retaining employees, including budtenders, who are in high demand within the industry.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Swiss Government to Launch Trial Cannabis Sales Program

Switzerland is set to become the first nation in Europe to launch a marijuana sales pilot program. The program, called Weed Care, will help study the effects of the legalization of marijuana. It will be launched officially on Sept. 15, 2022, and will run until March 2025.

Weed Care involves 370 participants based in Basel, the third most populous city in the country. All participants involved in the program reside in the city, are aged 18 and above, and are already consumers of cannabis. Throughout the study period, every participant will undergo regular assessments of their mental and physical health as well as their marijuana consumption behavior.

The country’s Federal Office of Public Health stated that the pilot program was aimed at increasing knowledge of the disadvantages and advantages of controlled access to marijuana and would offer a scientific basis to legalize adult-use marijuana in Switzerland.

The Federal Office of Public Health authorized the marijuana sales pilot program on April 19, 2022. The program will be conducted jointly by the University of Basel, the Department of Health of the Basel-Stadt Canton and the University Psychiatric Clinics. Basel health department’s medical director, Lukas Engelberger, stated that the pilot project was the first in the country, highlighting that prohibition hadn’t caused a drop in consumption, which warranted the need to test new regulatory models.

In an interview, Regine Steinauer, the addiction department head at Basel University, stated that the researchers were focused on finding out whether consumption changed, but they would also look into any physical and mental health changes observed when marijuana was consumed.

After showing their IDs, the study’s participants will be able to purchase two types of hashish-based products and four types of marijuana products from the pharmacies taking part in the study. The pharmacies will sell marijuana-based products based on the price determined by the illicit market, which is between $8 and $12. Products that contain different levels of THC will be produced by Pure Production, which is based in Switzerland.

Levels of THC in hashish products vary between 13%—20% while dried flowers contain a THC level between 5%—7%.

It should be noted that the country’s law prohibits the possession of more than 10 grams of marijuana, which limits study participants to purchasing no more than 10 grams of cannabis products in pharmacies. The law also doesn’t allow the public consumption of cannabis, so participants will have to consume the products in private locations.

When the pilot project registers success and the government fully opens a regulated market for cannabis, entities that have an interest in playing at an international level, such as Flora Growth Corp. (NASDAQ: FLGC), could find themselves with a window to further penetrate the European market.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – AROYA Expands Cutting-Edge Platform to Add Automated Irrigation Control

AROYA, a METER Group company, today unveiled Automated Irrigation Control as the latest crop steering enhancement to its industry leading AROYA Cannabis Production Platform. Crop steering technology enables operators of all sizes to bring out the best features of each cultivar. “Many craft farmers remain committed to their tried-and-true manual methods, like physically pouring run-off into milliliter cups, taking notes and running tests by hand,” said AROYA CEO Scott Campbell. “And to their credit, these purists are having success. However, for the independent purists, failing to embrace cultivation and production technology will be their demise. In addition to competition from larger operators, many smaller outfits have gone all-in with crop steering, advanced drying and analytics… Scalability through repeatable processes that ensure consistent outputs is the quintessential advantage for successful cannabis cultivation. With AROYA’s new offering, growers can replicate irrigation schedules and attach them to harvest groups/recipes without having to start from zero with each new grow cycle.”

To view the full press release, visit https://cnw.fm/KFku6

About AROYA

AROYA is a cannabis production platform that combines industry leading hardware and software to help cultivators increase yield, scale operations and achieve consistent quality. Based in Pullman, Washington, and a division of METER Group Inc., AROYA optimizes and demystifies the entire cannabis production process from seed to package. For additional information, please visit www.AROYA.io.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Oklahoma Voters May Not Decide Fate of Cannabis Measure Despite Ample Signature Submission

Voters in Oklahoma may not get the chance to vote on cannabis legalization during the upcoming November ballot even though reform activists behind a cannabis legalization measure collected enough signatures. Even though state officials confirmed that activists had reached the signature threshold, the campaign still needs to fulfill a few formalities before the deadline for printing voting materials passes.

Last month, the Oklahomans for Sensible Marijuana Laws (OSML) campaign announced that it had submitted more than 164,000 signatures to the Oklahoma secretary of state’s office, surpassing the signature threshold that was needed by more than 50,000 signatures. The campaign’s initiative would have allowed Oklahomans aged 21 and older to purchase and possess up to an ounce of cannabis. The legislation would also have allowed adults to cultivate a limited number of cannabis plants at home for personal use.

However, with the state deadline for printing voting material fast approaching, the fate of the initiative now hangs in the balance. Backed by New Approach PAC, the campaign will now take its initiative to the Supreme Court for review. If the court signs off on the signature count, the public will have 10 days to challenge the petitions’ validity.

According to Election Board Secretary Paul Ziriax, however, Aug. 29, 2022, is the deadline to officially certify measures for the November ballot. Furthermore, officials would have had to receive a gubernatorial proclamation of the ballot status by 5 p.m. on Friday, Aug. 26, 2022.  Ziriax said in a June letter that the “practical deadline” is meant to give county election boards enough time to prepare ballots to meet the 34-day deadline for sending absentee ballots to military voters who are overseas.

The OSML campaign bristled at the deadline’s introduction, calling it artificial and asking the Supreme Court to ensure that voters will be able to vote on the cannabis legalization measure on the November ballot. Oklahomans are more than ready for the creation of sensible marijuana laws rather than blanket criminalization, the campaign stated in a Twitter post, and the insane number of signatures it managed to collect are proof of this sentiment.

Observers believe the signature verification process has taken longer than usual this year because the secretary of state’s office outsourced the verification process to a third-party company, Western Petition Systems, rather than handling the process internally. This administrative delay has taken twice as long as when the secretary of state verified the signatures itself; the delay could prevent the bill from making it to the November ballot, Oklahoma Watch says.

The uncertainty surrounding whether or not Oklahoma voters will be able to make their voices heard regarding the proposed change in marijuana policy in the state is indicative of the huge obstacles that the marijuana industry and ancillary companies such as Advanced Container Technologies Inc. (OTC: ACTX) have to face in order to serve the customers who need their products, such as the equipment used in vertical cultivation indoors.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — How Missouri Activists Overcame Setbacks to Put Cannabis Measure on Upcoming Ballot

Cannabis reform activists in Missouri have managed to get their legalization bill on the November ballot after being bogged down by setbacks and nearly forced to give up on their bill. According to unofficial tallies, the Legal Missouri campaign had not collected enough signatures to qualify for the upcoming ballot by late July, being 2,275 signatures short. With the ballot fast approaching, many feared the campaign’s hope of gathering enough signatures in time would be dashed.

But activists behind the campaign managed to pull a major comeback, collecting the remaining 2,275 signatures by Aug. 9, 2022, and qualifying the legalization initiative for the upcoming ballot.

Missouri officials announced in early August that the Legal Missouri campaign had collected the required number of signatures and that the organization’s cannabis legalization measure would appear on Missouri’s November ballot.

Speaking at a press conference, Secretary of State Jay Ashcroft urged Missouri residents to educate themselves on ballot initiatives, including Initiative 2022-59, which he called “particularly lengthy.”

Before the Legal Missouri campaign managed to cover the deficit of signatures, it asked Ashcroft’s office to do an internal review of the signatures it had submitted, even providing the office with a list of signatures it believed had been disqualified incorrectly. Even though state law required that the campaign take its grievances to the court, this surprise maneuver worked, a feat that shocked even veterans who have been in the initiative petition game for years.

Attorney Chuck Hartfield said he has never seen an instance where such corrections were made outside of the court process in his years of representing initiative petition campaigns.

In May, the campaign had submitted around 400,000 signatures for its cannabis legalization initiative, and state law required that they achieve a signature threshold in at least six of Missouri’s eight congressional districts. Early reporting indicated that the campaign was falling behind in two congressional districts, with the campaign stating at the time that it was checking the results from officials for errors and that it was confident the initiative would qualify.

In a press release in early August, Legal Missouri 2022 campaign manager John Payne said that volunteers collected 100,000 signatures on top of those obtained by paid signature collectors, showing that there is plenty of grassroots support among Missouri residents who would like to legalize cannabis in the state. He said that if the signatures had not been reviewed, Missourians wouldn’t have had the chance to vote on cannabis legalization on the upcoming ballot, potentially making Missouri the 20th state to legalize recreational cannabis.

The resilience displayed by the advocates to ensure that the ballot initiative qualifies for the November polls exemplifies how the entire marijuana industry and its actors, such as American Cannabis Partners, go to great lengths to make progress despite insurmountable odds.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces the Availability of a Broadcast titled, “The Power of Science to Stop a Killer”

  • Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point
  • Since the company began developing its patented DehydraTECH(TM) technology in 2014, it has made significant progress in its clinical studies, even as it currently focuses on human clinical research to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment
  • Lexaria expressed its confidence in its proposed solution, noting that it will not only be a safer but also better-tolerated drug candidate, unlike current alternatives in the market whose side effects far outweigh their benefits
  • The company looks to capitalize on the growing global anti-hypertensive drugs market, which is projected to hit $27.81 billion in value by 2025, and maintains that should it sustain the results achieved in recent hypertension studies, then it could be looking at mega-drug status ($1 billion per year) in the hypertension market

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its latest addition to a growing body of corporate communication pieces in its line-up. Titled “The Power of Science to Stop a Killer,” this recent broadcast highlights the company’s progress in finding a potential solution for hypertension treatment, while also pointing out why a solution is much needed at this point (https://cnw.fm/6E6Dy).

Lexaria’s flagship offering, its patented DehydraTECH(TM) technology, has proven to improve ways through which active pharmaceutical ingredients (“APIs”) enter the bloodstream, primarily by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.

This overall effectiveness has seen the technology’s application in various segments, including but not limited to nicotine replacement, CBD, antivirals, epilepsy, human hormones, and PDE5 inhibitors. Lexaria’s venture into the hypertension sector acknowledges that over 114 million adults in the United States are at risk of damage caused by hypertension. In addition, the condition contributed to over 670,000 deaths within the country in 2020 alone (https://cnw.fm/bzEwy).

In this broadcast, Lexaria highlighted the progress it has made in its clinical studies and its success so far, ever since it began developing DehydraTECH in 2014. Furthermore, it expressed its confidence that its proposed solution will not only be safer but also a better-tolerated drug candidate, unlike current alternatives in the market whose side effects far outweigh their benefits.

Lexaria has made significant advancements in its clinical processes, amassing a growing body of evidence that strongly supports the use of its technology in hypertension therapeutics. This is not just a relief to millions of patients living with the condition but also a welcome addition for the company’s shareholders. In the communication, Lexaria noted that its valuation looks attractive with arguably significant upside. As a result, it looks to rub shoulders and gain attention from the likes of Pfizer Inc. (NYSE: PFE), Merc & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN), and Novartis AG (NYSE: NVS).

ReportLinker projects that the global anti-hypertensive drugs market will be valued at $27.81 billion by 2025, up from $24.17 billion in 2020, representing a compound annual growth rate (“CAGR”) of 0.8% (https://cnw.fm/714TS). For comparison, each year, the United States spends an average of $131 billion in hypertension costs, with figures expected to go up, particularly given the low awareness of anti-hypertensive drugs amongst the population.

Lexaria is optimistic that with its DehydraTECH technology, hypertension treatment will not only be more accessible but also more efficient and effective, ultimately allowing for a better quality of life for patients and a healthier, more productive population.

The company is currently focusing on human clinical studies to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment. In addition, it is inching closer to approval by the United States Food and Drug Administration (“FDA”), having received positive feedback from the institution on its DehydraTECH-CBD proposals earlier this month (https://cnw.fm/uLYzv).

Lexaria’s management still maintains late 2022/early 2023 for its Investigational New Drug (“IND”) application with the FDA and remains confident that should it sustain the results achieved in recent hypertension studies, then it could be looking at mega-drug status ($1 billion per year) in the hypertension market.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Recent Studies Show Advanced Cancer Sufferers Could Benefit from Using Marijuana

Over the past couple of years, a surge in cannabis research has revealed that the controversial plant has a variety of medical applications. Despite being classified as a Schedule I drug with no medical application, studies have found that cannabis can be effective at alleviating conditions such as chronic pain, depression and insomnia. Furthermore, the U.S. Food and Drug Administration has also approved a CBD-based drug called Epidiolex to treat seizures in pediatric epilepsy.

In recent months, research into the impact of cannabis on cancer treatment has found that the plant can have a positive impact on cancer patients. Cancer is one of the deadliest killers in the country, taking more than 500,000 lives per year and costing billions of dollars for treatment. Although there are treatments that can stop cancers from growing and significantly increase patients’ quality of life, no cure for cancer currently exists.

Researchers have been working on developing new treatments for the deadly disease, with cannabis being one of the objects of interest. Cancer is often associated with costly and addictive pain medications, reduced life quality, and mental and emotional anguish. And while most cancer treatments are geared at alleviating physical discomfort, there are barely any treatments designed to treat the mental and psychological anguish that comes from having a severe or terminal illness.

Upstate University Hospital researchers sought to understand how cannabis could benefit cancer treatment by studying how advanced cancer patients reacted to medical cannabis treatment.  Study authors write that the goal of the research was to analyze the characteristics of advanced cancer patients who had received medical cannabis under a palliative care program and to point out any barriers that prevent patients with cancer from accessing medical marijuana.

Study participants had to be enrolled in New York’s medical cannabis registry. Researchers from the Upstate University Hospital in Syracuse reviewed patient data that was collected from June 2017 to June 2020, analyzing data from patients who had been diagnosed with cancer by a practitioner who is certified by the New York Medical Marijuana program and who had received treatment at Upstate Medical University.

The researchers found that medical cannabis use had a positive impact on advanced cancer patients, with 48.14% of the patients who received a dose of medical marijuana reporting reduced pain, 44.95% saying that they used fewer opioids as a result, and 85.11% noting that cannabis use alleviated at least one symptom. Only 3.72% of the patients who used cannabis reported feeling any adverse effects.

Researchers concluded that medical cannabis seems to play a role in alleviating symptoms of advanced cancer with minimal side effects and called for more research to determine optimal delivery methods and doses for patients. In this regard, industry players such as Cannabis Strategic Ventures Inc. (OTC: NUGS) are leading the way by coming up with different innovations that optimize consumers’ experience while using marijuana products.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Marijuana Firms in Virginia Expand Facilities Despite Uncertainty Over Recreational Sales

Last year, legislators in Virginia approved a measure to legalize its commercial recreational cannabis market and launch it in 2024, which would make it the first of its kind in the South. At the time, Democrats were in control of the state’s government. However, once Republicans reclaimed the governor’s mansion and the House of Delegates in November, whether the state’s adult-use program would actually be launched at the stipulated time was thrown into disarray.

Despite this, marijuana multistate operators remain focused on expanding their medical cannabis facilities. For instance, representatives from Columbia Care and Jushi Holdings have revealed that their central focus is on launching six dispensaries each, as permitted under state law. Jushi Holdings, which is based in Florida, and Columbia Care, which is based in New York, have medical marijuana licenses in the state of Virginia. Both firms also plan to expand related infrastructure such as manufacturing facilities and grow rooms.

Trent Woloveck, Jushi’s chief commercial director, stated that the company was expanding its full complement of grow rooms. He also revealed the company had opened its third store last month in Alexandria. Jushi Holdings also has dispensaries operating in Sterling and Manassas and plans to launch its Fairfax store soon. Construction has also begun for the firm’s fifth store, which will be located in Arlington, with work to finalize its sixth site in Woodbridge also ongoing.

On the other hand, Columbia Care has four dispensaries located in Virginia: Short Pump, Richmond, Virginia Beach and Portsmouth. The company’s vice president of public policy, Ngiste Abebe, stated that the company was focused on launching more locations so that they could serve as many customers as possible.

The companies are focused on the state of Virginia because the legislature made significant changes to its medical cannabis program, which included streamlining applications, which would enable patients to purchase products as soon as they obtained a physician’s recommendation. This is expected to increase demand.

Prior to these changes, patients who received a doctor’s medical marijuana recommendation had to wait at least half a year to receive the paperwork required from the Board of Pharmacy in the state.

The state’s medical cannabis program also continues to grow, laying the foundation for a recreational marijuana market. Projections show that the medical cannabis market in Virginia will rake in about $25 million in sales in 2022. This figure is expected to increase to $95 million in less than four years.

While there is still uncertainty regarding whether recreational sales will be launched on schedule in Virginia, the existing law offers hope that change is coming and that the industry and its leading actors such as Prime Harvest Inc. will witness reforms taking place in different jurisdictions at an increasing rate in the years to come.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.